The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMpac Group Plc Regulatory News (MPAC)

Share Price Information for Mpac Group Plc (MPAC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 440.00
Bid: 435.00
Ask: 445.00
Change: 0.00 (0.00%)
Spread: 10.00 (2.299%)
Open: 437.50
High: 440.00
Low: 437.50
Prev. Close: 440.00
MPAC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Molins Plc

20 May 2014 11:32

RNS Number : 5805H
AIM
20 May 2014
 



 

 

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Molins PLC

 

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

Rockingham Drive

Linford Wood East

Milton Keynes

MK14 6LY

 

COUNTRY OF INCORPORATION:

England and Wales

 

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.molins.com

 

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

The principal activities of Molins PLC (the "Company or the "Group") are the design, manufacture and servicing of processing and quality control instrumentation and machinery and the provision of analytical laboratory services for the fast-moving consumer goods, healthcare and pharmaceutical sectors. The Group is organised into three divisions - Scientific Services, Packaging Machinery and Tobacco Machinery.

 

The Group's main country of operation is the UK with its registered office and head office based in Milton Keynes. The Group's overseas locations include facilities and offices in the USA, Canada, Russia, the Netherlands, the Czech Republic, Singapore and Brazil.

 

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

20,171,540 ordinary shares of 25 pence each.

 

No shares are held in treasury.

 

The shares are freely transferable and have no restrictions placed on them.

 

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Capital to be raised on admission: n/a

 

Anticipated market capitalisation on admission: £35 million

 

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

30.3%

 

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED:

None

 

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Avril Palmer-Baunack (Chairman)

Richard (Dick) Clive Hunter (Chief Executive)

David John Cowen (Group Finance Director)

John Lewis Davies (Non-Executive Director)

Philip James Moorhouse (Non-Executive Director)

 

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Shareholders as at before and after admission:

 

Schroder Investment Management Limited

26.08%

Barclays Wealth

6.06%

River & Mercantile Asset Management LLP

5.78%

Charles Stanley

5.06%

Hargreaves Lansdowne Asset Management

4.27%

TD Direct Investing

3.75%

EES Trustees International Limited

3.38%

Mr G V L Oury

3.07%

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

None

 

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

(i) 31 December

(ii) n/a

(iii) 30 September 2014 (interim results for the six month period to 30 June 2014)

30 June 2015 (annual results for the full year to 31 December 2014)

30 September 2015 (interim results for the six month period to 30 June 2015)

 

EXPECTED ADMISSION DATE:

19 June 2014

 

NAME AND ADDRESS OF NOMINATED ADVISER:

Panmure Gordon (UK) Limited

One New Change

London

EC4M 9AF

United Kingdom

 

NAME AND ADDRESS OF BROKER:

Panmure Gordon (UK) Limited

One New Change

London

EC4M 9AF

United Kingdom

 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

n/a

 

DATE OF NOTIFICATION:

20 May 2014

 

NEW/ UPDATE:

NEW

 

QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:

THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED:

Premium segment of the UKLA Official List / Main Market of the London Stock Exchange

 

THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED:

28 July 1976

 

CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORY REQUIREMENTS INVOLVED IN HAVING ITS SECURITIES TRADED UPON SUCH A MARKET OR DETAILS OF WHERE THERE HAS BEEN ANY BREACH:

The Company has adhered to the legal and regulatory requirements of the Official List / Main Market.

 

AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THE LAST TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE:

www.molins.com

 

DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING STRATEGY:

The Company's strategy to achieve its objective of growth across its three divisions can be summarised as follows:

 

-

Increasing the Group's exposure to attractive global industry sectors - nutrition, beverages, healthcare, pharmaceuticals and tobacco

-

Investment in the development of innovative new products and services, the Group's infrastructure and acquisitions in adjacent growth markets

-

Driving operational efficiency through supply chain and customer service excellence, capitalising on opportunities to realise synergies

 

A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURRED SINCE THE END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED:

There has been no significant change in the financial or trading position of Molins PLC since 31 December 2013, being the end of the last financial period for which audited financial statements have been published.

 

A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT THE WORKING CAPITAL AVAILABLE TO IT OR ITS GROUP WILL BE INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION:

The Directors of Molins PLC have no reason to believe that the working capital available to the Company or its Group will be insufficient for at least 12 months from the date of its admission.

 

DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES:

None

 

A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES:

Settlement will be through the CREST system for dealings in ordinary shares held in uncertificated form. Shares can also be dealt with in certificated form.

 

A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES:

www.molins.com

 

INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC:

See Appendix 1, available at www.molins.com

 

A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE A FINANCIAL YEAR END NOT MORE THEN NINE MONTHS PRIOR TO ADMISSION AND INTERIM RESULTS WHERE APPLICABLE. THE ACCOUNTS MUST BE PREPARED IN ACCORDANCE WITH ACCOUNTING STANDARDS PERMISSIBLE UNDER AIM RULE 19:

www.molins.com/investor-relations/financial-information

 

THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TREASURY:

None

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PAABGGDUBXDBGSG
Date   Source Headline
26th Apr 20247:35 amRNSSiSTEM pilot battery assembly line
17th Apr 20247:00 amRNSLaunch of ESG Report
9th Apr 20241:12 pmRNSGrant of Options
8th Apr 20242:15 pmRNSNotice of AGM
19th Mar 20247:00 amRNSFull Year Results
21st Feb 20247:00 amRNSEquity Development Investor Presentation
16th Feb 20247:00 amRNSNotice of Results
11th Jan 20247:00 amRNSFull Year Trading Update
4th Dec 202311:51 amRNSDirector/PDMR Shareholding
27th Nov 202311:36 amRNSDirector/PDMR Dealing
18th Oct 20232:42 pmRNSHolding(s) in Company
12th Oct 20237:00 amRNSAppointment of Joint Broker
22nd Sep 202311:19 amRNSHolding(s) in Company
7th Sep 20237:00 amRNSHalf Year Results
17th Aug 20237:00 amRNSEquity Development Investor Webinar
11th Jul 20237:00 amRNSTrading Update and Notice of Results
30th May 202310:52 amRNSDirector/PDMR Shareholding
18th May 202311:17 amRNSResult of Annual General Meeting
17th May 20237:00 amRNSAGM Statement
2nd May 20234:37 pmRNSDirector/PDMR Transaction
6th Apr 20235:30 pmRNSAvailability of Annual Report and Notice of AGM
27th Mar 202310:53 amRNSDirector/PDMR Dealing
22nd Mar 20237:01 amRNSCEO succession
22nd Mar 20237:00 amRNSFull Year Results
20th Feb 20237:00 amRNSEquity Development Investor Presentation
17th Feb 20237:00 amRNSNotice of Results
16th Jan 20237:00 amRNSFull Year Trading Update
24th Oct 20222:20 pmRNSDirectorate Appointment
14th Oct 202210:58 amRNSReplacement - PDMR Dealing & Total Voting Rights
12th Oct 20224:59 pmRNSDirector/PDMR Dealing & Total Voting Rights
15th Sep 202212:50 pmRNSMpac signs FREYR framework agreement
13th Sep 20227:00 amRNSEquity Development Investor Presentation
9th Sep 20222:16 pmRNSDirector/PDMR Transaction
8th Sep 20227:00 amRNSHalf Year Result
11th Jul 20227:00 amRNSTrading Update and Notice of Results
24th Jun 20222:54 pmRNSAppointment of new auditor
10th Jun 20224:10 pmRNSGrant of Options
27th May 20222:56 pmRNSDirectors/PDMRs Dealing
25th May 20224:13 pmRNSHolding(s) in Company
19th May 20223:57 pmRNSEBT Subscription & Total Voting Rights
13th May 20224:25 pmRNSDirectors/PDMRs Dealing - Replacement
12th May 20224:46 pmRNSDirectors/PDMRs Dealing
4th May 20224:16 pmRNSResult of AGM
4th May 20227:00 amRNSAGM Statement
17th Mar 20227:00 amRNSFull Year Results
14th Feb 20224:38 pmRNSNotice of Results
12th Jan 20227:00 amRNSFull Year Trading Update
21st Oct 20215:16 pmRNSDirectorate Appointment
2nd Sep 20217:00 amRNSHalf Year Results
13th Aug 20217:00 amRNSEquity Development Investor Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.